Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lance Leopold, MD
Ascenta Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
San Diego, California, United States
- Facility name not stated
Atlanta, Georgia, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Boston, Massachusetts, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Rochester, New York, United States
- Facility name not stated
High Point, North Carolina, United States
- Facility name not stated
Hilton Head Island, South Carolina, United States
- Facility name not stated
Memphis, Tennessee, United States
- Facility name not stated
Burlington, Vermont, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2005
- Primary completion
- 31 Dec 2008
- Completion
- 31 Dec 2008
- Last update posted
- 29 Jun 2011
- Registered enrollment
- 50
- Registry id
- NCT00275431
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.